Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001171923 | SCV001334826 | uncertain significance | not provided | 2020-03-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001312516 | SCV001502972 | uncertain significance | Immunodeficiency, common variable, 2 | 2024-11-06 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 260 of the TNFRSF13B protein (p.Gly260Glu). This variant is present in population databases (rs150660451, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with TNFRSF13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 916321). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on TNFRSF13B protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001171923 | SCV002584078 | uncertain significance | not provided | 2022-04-14 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Prevention |
RCV003393861 | SCV004118910 | uncertain significance | TNFRSF13B-related disorder | 2023-10-01 | criteria provided, single submitter | clinical testing | The TNFRSF13B c.779G>A variant is predicted to result in the amino acid substitution p.Gly260Glu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0071% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/17-16842964-C-T). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |